IRIS Institutional Research Information System - OPENBS Open Archive UniBS

NODARI, SAVINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 38.328
AS - Asia 21.756
EU - Europa 19.202
SA - Sud America 4.223
Continente sconosciuto - Info sul continente non disponibili 575
AF - Africa 441
OC - Oceania 96
AN - Antartide 2
Totale 84.623
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 37.248
CN - Cina 7.661
SG - Singapore 7.359
UA - Ucraina 5.281
IT - Italia 4.274
BR - Brasile 3.581
HK - Hong Kong 2.425
DE - Germania 2.250
FR - Francia 1.571
FI - Finlandia 1.261
GB - Regno Unito 1.183
IN - India 1.156
TR - Turchia 900
VN - Vietnam 871
PL - Polonia 835
IE - Irlanda 810
RU - Federazione Russa 735
CA - Canada 586
SE - Svezia 343
BD - Bangladesh 315
AR - Argentina 234
MX - Messico 223
IQ - Iraq 170
NL - Olanda 162
ID - Indonesia 126
JP - Giappone 126
ES - Italia 110
CO - Colombia 104
ZA - Sudafrica 103
PK - Pakistan 97
EC - Ecuador 96
SA - Arabia Saudita 95
AU - Australia 83
BE - Belgio 72
KE - Kenya 60
UZ - Uzbekistan 58
VE - Venezuela 57
EG - Egitto 54
CR - Costa Rica 51
MY - Malesia 51
NG - Nigeria 51
AT - Austria 48
MA - Marocco 47
PY - Paraguay 46
JM - Giamaica 42
MU - Mauritius 41
CL - Cile 38
CH - Svizzera 34
PH - Filippine 33
TW - Taiwan 32
EU - Europa 31
NP - Nepal 31
TN - Tunisia 31
NO - Norvegia 29
TT - Trinidad e Tobago 29
AE - Emirati Arabi Uniti 27
NI - Nicaragua 27
PE - Perù 25
UY - Uruguay 25
KR - Corea 24
HN - Honduras 23
PT - Portogallo 21
CZ - Repubblica Ceca 20
IR - Iran 20
JO - Giordania 20
LT - Lituania 20
KZ - Kazakistan 19
TH - Thailandia 19
BG - Bulgaria 18
IL - Israele 18
LB - Libano 17
BB - Barbados 16
RO - Romania 16
GT - Guatemala 15
OM - Oman 15
AZ - Azerbaigian 14
ET - Etiopia 14
HU - Ungheria 14
SV - El Salvador 14
AL - Albania 13
BO - Bolivia 13
DZ - Algeria 13
NZ - Nuova Zelanda 13
PR - Porto Rico 12
BH - Bahrain 11
HR - Croazia 10
MD - Moldavia 10
DO - Repubblica Dominicana 9
PA - Panama 9
RS - Serbia 9
SY - Repubblica araba siriana 8
BA - Bosnia-Erzegovina 7
EE - Estonia 6
GR - Grecia 6
KG - Kirghizistan 6
KW - Kuwait 6
LK - Sri Lanka 6
LV - Lettonia 6
SK - Slovacchia (Repubblica Slovacca) 6
BZ - Belize 5
Totale 83.985
Salva come PNG Salva come JPEG
Città #
Singapore 3.843
Jacksonville 3.836
Ashburn 3.783
Hong Kong 2.406
San Jose 2.047
Fairfield 1.973
Chandler 1.945
Woodbridge 1.702
Princeton 1.551
Nanjing 1.416
Beijing 1.409
The Dalles 1.409
Ann Arbor 1.244
Council Bluffs 1.243
Houston 1.225
Wilmington 1.218
Cambridge 1.051
New York 986
Columbus 803
Warsaw 802
Dublin 800
Seattle 731
Istanbul 690
Lauterbourg 682
Los Angeles 595
Nanchang 534
Helsinki 468
Milan 466
São Paulo 429
Buffalo 403
Des Moines 384
Hebei 341
Shenyang 324
Ho Chi Minh City 314
Moscow 304
Rome 274
Changsha 258
Tianjin 236
Jiaxing 230
Dallas 216
Santa Clara 200
San Diego 189
Kunming 180
Toronto 177
Hanoi 173
Dearborn 167
San Francisco 158
Verona 155
Redondo Beach 151
Jinan 149
Orem 142
Chicago 140
Brescia 135
Hangzhou 134
Shanghai 115
Kocaeli 114
Rio de Janeiro 111
Phoenix 110
Mexico City 101
Newton 101
Boardman 93
Tokyo 90
Brooklyn 87
Munich 81
Naples 81
Atlanta 80
London 80
Guangzhou 76
Zhengzhou 76
Chennai 75
Frankfurt am Main 73
Lancaster 71
Belo Horizonte 70
Florence 70
Manchester 62
Vancouver 62
Denver 61
Ningbo 61
Brasília 60
Montreal 58
Bologna 56
Baghdad 55
Lanzhou 55
Charlotte 54
Norwalk 53
Nairobi 52
Tashkent 52
Changchun 51
Brussels 50
Taizhou 49
Abuja 48
Boston 47
Curitiba 47
Porto Alegre 47
Palermo 46
Pune 43
Salvador 43
Catania 42
Nuremberg 42
Guarulhos 41
Totale 49.913
Salva come PNG Salva come JPEG
Nome #
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 1.446
Un caso di Sindrome di Bland-White-Garland: origine anomala dell’arteria coronaria sinistra dall’arteria polmonare. 745
Inodilatatori: perché e quali. 418
Livelli circolanti del marcatore tumorale CA 125 in pazienti con scompenso cardiaco cronico:relazione con la classe NYHA, i parametri ecocardiografici e variazioni indotte dalla terapia. 410
Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial) 382
Il genotipo DD per il gene dell’enzima di conversione dell’angiotensina identifica i pazienti con insufficienza cardiaca che possono beneficiare di dosi medio elevate di ACE inibitori. 375
Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance 355
Valutazione dell’indice di performance miocardica (MPI) del ventricolo destro con studio eco-doppler in pazienti affetti da insufficienza cardiaca. 351
L’ indice di performance miocardica ( MPI ) è un importante indicatore prognostico nei pazienti affetti da insufficienza cardiaca cronica. 295
I polimorfismi Arg16 Gly del gene recettore beta-2 adrenergico influenzano i parametri emodinamici e la prognosi dei pazienti con insufficienza cardiaca. 281
Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. 276
Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study 275
I polimorfismi Arg16Gly del gene recettore beta-2 adrenergico influenzano i parametri emodinamici e la prognosi dei pazienti con insufficienza cardiaca 273
Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. 238
Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold 233
Effects of supplementation with polyunsaturated fatty acids in patients with heart failure. 229
Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy 218
Efficacia di un nuovo diuretico, la muzolimina, in pazienti con insufficienza cardiaca. 206
Clinical trials update from the World Congress of Cardiology 2006. 205
1Beta-2 adrenergic receptors gene polymorphisms influence the effects of carvedilol in the patients with heart failure. 202
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy 202
A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension. 201
The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. 200
Fattori di rischio ed “epidemiologia inversa” nei pazienti con insufficienza cardiaca. 199
Valvola aortica quadricuspide asintomatica : un caso clinico. 199
Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: Findings from the ASTRONAUT trial 196
Determinazione dell’equilibrio simpato-vagale attraverso l’analisi spettrale della variabilità della frequenza cardiaca in pazienti con insufficienza cardiaca di diverso grado di severità. 194
A rationale for the use of BETA-blockers as standard treatment for heart failure 193
Serum levels of different tumoral markers in patients with congestive heart failure. 188
Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review 187
A randomized double blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant hypertension. Ca+ Nicardipine. Selected reports from the worldwide literature. 183
Are Beta-1 and alpha2c-adrenergic receptor polymorphisms associated with an increased risk of heart failure in Caucasian subjects: results of a case-control study 182
Beta- adrenergic receptors polymorphisms and response to CRT 181
Significato prognostico indipendente della frequenza cardiaca a riposo alla dimissione come predittore di mortalità in pazienti ricoverati per insufficienza cardiaca acuta. 176
Acute hemodynamic effects of the two dopaminergic agonists ibopamine and dihydroergotamine, a comparison with the parent compound. 175
Cardiovascular and non cardiovascular comorbidities in patients with chronic heart failure. 175
Valore prognostico delle variazioni dell'indice di distribuzione dei volumi eritrocitari (RDW) nello scompenso cardiaco cronico. 173
Acute heart failure syndromes: assessment and reconstructing the heart. 172
The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T 171
Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists 171
Raised homocystein plasma concentration in patients with heart failure: Clinical significance 169
Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial) 168
Anemia and heart failure : a cause of progression or only a consequence? 166
Prognostic Value of Serial Clinical, Laboratory and Ecocardiographic Tests in Ambulatory Patients with Chronic Heart Failure 165
Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients with Chronic Heart Failure 163
Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report. 162
Clinical significance of Beta-adrenergic receptor polymorphisms in the patients with chronic heart failure 162
Effects of aldosterone blockers on left ventricular function and remodeling in patients with mild-moderate chronic heart failure. 161
Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study. 160
A randomized comparison of the effects of metoprolol and carvedilol on the hemodynamics and functional capacity of patients with heart failure. 158
The 6-min walking test early after cardiac surgery. Reference values and the effects of rehabilitation programme. 157
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial 157
Acute antianginal efficacy and duration of action of isosorbide 2-mononitrate. 156
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial 156
Prognostic value of serial measurements of blood urea nitrogen in ambulatory patients with chronic heart failure 156
Acute hemodynamic and neurohumoral effects of the oral dopamine derivative ibopamine in patients with heart failure. 153
A new dopamine derivative, ibopamine, in the chronic treatment of heart failure: one year follow-up. 153
Cardiovascular and neurohumoral effects of the administration of reboxetine to health volunteers. 152
Nutritional Supplementation with Amino Acids in Ambulatory Patients with Idiophatic Dilatated Cardiomyophaty 152
[Chronic heart failure therapy: where we are and where we are going to] 152
n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. 150
Cardioversione elettrica transtoracica della fibrillazione atriale eseguita in Day-Hospital: efficacia a medio termine. 149
Asse cuore-rene nell’iperteso cardiopatico. 147
A Current treatment in acute and chronic cardio-renal syndrome. 147
Ruolo prognostico della fibrinogemia in pazienti diabetici ricoverati per sindrome coronarica acuta. 146
Influence of the angiotensin-converting enzyme genotype on the response to the beta-blocker therapy and the prognosis of the patients with chronic heart failure. 145
Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial) 145
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial 145
Acute and chronic effects of nisoldipine in patients with chronic heart failure. 144
Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. 143
The chronic heart failure evolutions: Different fates and routes 142
Independent role of resting heart rate at discharge as a predictor of mortality after hospitalisation for acute heart failure. 142
Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction 142
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion 142
A new educational program in heart failure drug development: The Brescia international master program 142
Time corse and prognostic value of NT-proBNP plasma levels in the patients with acute heart failure. 141
Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies 141
Six-year prognosis of diabetic patients with coronary artery disease. 140
Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score 140
Response to the letter of Hester Den Ruijter and Ruben Coronel regarding the article "the role of n-3 pufas in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy" 139
[Italian Society of Cardiology (SIC) Position paper: Technical, instrumental and standards of interpretation for electrocardiography, ambulatory electrocardiographic and blood pressure monitoring in telemedicine] 138
Scompenso cardiaco: meccanismi fisiopatologici e definizioni. 138
Clinical cases of Churg-Strauss syndrome and heart disease 138
Mediterranean diet impact on cardiovascular diseases: A narrative review 138
Weight loss favorably affects the cardiac sympatho-vagal balance of the obese patients: results of power spectral analysis of heart rate variability. 137
Abnormal hemodynamics and ventilatory response to exercise may identify chronic heart failure patients at high risk despite long term beta-blocker treatment. 137
Lack of association of coeliac disease with idiopathic and ischaemic dilated cardiomyopathies. 137
Role of worsening renal function in patients hospitalised for acute heart failure 136
Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization. 136
Valutazione emodinamica e neurormonale di tre agenti dopaminergici in pazienti con grave insufficienza cardiaca. 135
Le pressioni di riempimento ventricolari e la risposta ventilatoria allo sforzo identificano i pazienti con insufficienza cardiaca ad alto rischio di eventi nonostante la terapia beta-bloccante. 135
Il polimorfismo dei recettori B-2 adrenergici influenza la risposta al carvedilolo nei pazienti con insufficienza cardica cronica. 135
Role of fluid retention in patients hospitalised for acute heart failure. 135
Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms. 135
Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial 135
Maximal and submaximal exercise testing in heart failure. 135
Redefining biomarkers in heart failure 134
Rest and exercise effects of the acute and chronic administration of nisoldipine in patients with heart failure. 133
Le calcificazioni intracardiache all’esame ecocardiografico nella diagnosi differenziale tra cardiomiopatia dilatativa ischemica ed idiopatica. 133
Different prognostic values of clinical and metabolic parameters in ischaemic diabetic patients with preserved/impaired left ventricular function. 133
Totale 19.894
Salva come PNG Salva come JPEG
Categoria #
all - tutte 423.881
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 423.881
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.743 0 0 0 343 85 253 151 371 292 647 523 1.078
2022/20235.509 852 63 48 516 513 1.620 16 565 855 44 194 223
2023/20244.104 333 101 174 234 145 740 121 110 1.207 60 99 780
2024/202510.958 65 57 93 1.249 1.485 762 930 452 1.169 568 2.476 1.652
2025/202620.896 1.917 3.326 1.497 2.917 1.674 1.304 3.230 922 1.276 1.953 592 288
2026/20277.668 1.337 1.203 2.510 2.618 0 0 0 0 0 0 0 0
Totale 84.623